User profiles for "author:Simon Lal"

Simon Lal

University of Manchester
Verified email at srft.nhs.uk
Cited by 9452

Pre‐operative Nutrition Support in Patients Undergoing Gastrointestinal Surgery.

S Burden, C Todd, J Hill, S Lal - Cochrane Database of …, 2012 - cochranelibrary.com
Background Post‐operative management in gastrointestinal (GI) surgery is becoming well
established with'Enhanced Recovery After Surgery'protocols starting 24 hours prior to …

ESPEN guideline on home parenteral nutrition

L Pironi, K Boeykens, F Bozzetti, F Joly, S Klek, S Lal… - Clinical nutrition, 2020 - Elsevier
This guideline will inform physicians, nurses, dieticians, pharmacists, caregivers and other
home parenteral nutrition (HPN) providers, as well as healthcare administrators and policy …

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers

TA Lawrie, JT Green, M Beresford… - Cochrane Database …, 2018 - cochranelibrary.com
Background An increasing number of people survive cancer but a significant proportion
have gastrointestinal side effects as a result of radiotherapy (RT), which impairs their quality …

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

NA Kennedy, GA Heap, HD Green… - The lancet …, 2019 - thelancet.com
Background Anti-TNF drugs are effective treatments for the management of Crohn's disease
but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors …

ESPEN guidelines on chronic intestinal failure in adults

L Pironi, J Arends, F Bozzetti, C Cuerda, L Gillanders… - Clinical nutrition, 2016 - Elsevier
Summary Background & aims Chronic Intestinal Failure (CIF) is the long-lasting reduction of
gut function, below the minimum necessary for the absorption of macronutrients and/or water …

[HTML][HTML] HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease

A Sazonovs, NA Kennedy, L Moutsianas, GA Heap… - Gastroenterology, 2020 - Elsevier
Background & Aims Anti–tumor necrosis factor (anti-TNF) therapies are the most widely
used biologic drugs for treating immune-mediated diseases, but repeated administration can …

Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin

G Burdyga, S Lal, A Varro, R Dimaline… - Journal of …, 2004 - Soc Neuroscience
Both inhibitory (satiety) and stimulatory (orexigenic) factors from the gastrointestinal tract
regulate food intake. In the case of the satiety hormone cholecystokinin (CCK), these effects …

Vagal afferent responses to fatty acids of different chain length in the rat

S Lal, AJ Kirkup, AM Brunsden… - American Journal …, 2001 - journals.physiology.org
The role of cholecystokinin (CCK) in the effect of dietary lipid on proximal gastrointestinal
function and satiety is controversial. Recent work suggests that fatty acid chain length may …

Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views

CP Selinger, J Eaden, W Selby… - Journal of Crohn's …, 2013 - academic.oup.com
Background: Enabling women with inflammatory bowel diseases (IBD) to have successful
pregnancies requires complex decisions. The study aimed to assess patients' views on IBD …

Cannabis use amongst patients with inflammatory bowel disease

S Lal, N Prasad, M Ryan, S Tangri… - European journal of …, 2011 - journals.lww.com
Background Experimental evidence suggests the endogenous cannabinoid system may
protect against colonic inflammation, leading to the possibility that activation of this system …